Why the study?
Do DOACs provide similar efficacy and better safety compared to conventional treatment in patients with acute venous thromboembolism?
Do DOACs provide similar efficacy and better safety compared to conventional treatment in patients with acute venous thromboembolism?
DOACs are the standard of care for acute VTE due to similar efficacy and better safety compared to conventional heparin/VKA therapy.
Affirms DOAC preference in acute VTE; extends phase 3 RCT data to IR practice.
Anticoagulant therapy is the cornerstone of therapeutic management in acute venous thromboembolism (VTE), consisting of pulmonary embolism and deep vein thrombosis. Direct oral anticoagulants (DOACs) have become the standard of care because of their good safety profile and ease of use in clinical practice. Indeed, phase 3 randomized trials (AMPLIFY, EINSTEIN, RECOVER, and HOKUSAI studies) showed that DOACs provided a similar efficacy and a better safety than conventional treatment with parenteral heparin with overlapping loading dose of vitamin K antagonists in acute VTE therapeutic management. The results of published data from real-world registries confirm the safety and efficacy of DOACs demonstrated in the phase 3 trials.
No takes yet. Share an insight, caveat, or question.
Pol et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: